SCHEDULE: Citius Pharmaceuticals' Stake in Oncology Unit Diluted to 79.1%

Citius Pharmaceuticals, Inc.'s beneficial ownership in Citius Oncology, Inc. decreased to 79.1% following a registered direct offering by the subsidiary.

Summary

• Citius Pharmaceuticals, Inc. (the "Reporting Person") now beneficially owns 66,049,615 shares of Citius Oncology, Inc. common stock.
• This represents approximately 79.1% of Citius Oncology, Inc.'s total outstanding common stock.
• The updated ownership is based on 83,513,442 shares of common stock outstanding as of September 10, 2025.
• The change in ownership percentage is a result of Citius Oncology, Inc. selling and issuing 5,142,858 shares of its common stock in a registered direct offering on September 10, 2025.
• The Reporting Person retains sole voting and dispositive power over its 66,049,615 beneficially owned shares.

Sentiment

Score: 5

Explanation: The filing is a factual update on beneficial ownership following a share issuance. While the subsidiary raised capital, the reporting person's percentage ownership was diluted, which is a slight negative from an ownership control perspective, but not necessarily a negative for the subsidiary's operations if capital was needed.

Positives

• Citius Oncology, Inc. successfully raised capital through a registered direct offering by issuing 5,142,858 shares.
• Citius Pharmaceuticals, Inc. maintains a significant majority stake (79.1%) in Citius Oncology, Inc., indicating strong control and strategic alignment.

Negatives

• Citius Pharmaceuticals, Inc.'s percentage ownership in Citius Oncology, Inc. decreased from an implied 84.28% to 79.1% due to the subsidiary's registered direct offering, indicating dilution of its controlling stake.

Risks

• Dilution of existing shareholders' stake in Citius Oncology, Inc. due to the issuance of new common stock.
• Potential impact on market perception of Citius Oncology, Inc. following a registered direct offering, depending on the terms and use of proceeds (not detailed in this specific filing).

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding future operations or financial performance of Citius Oncology, Inc. or Citius Pharmaceuticals, Inc. beyond the current ownership structure.

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct." (Signed by Leonard Mazur, Chief Executive Officer of Citius Pharmaceuticals, Inc.)

Industry Context

This filing primarily concerns a change in beneficial ownership percentage for a parent company in its subsidiary, rather than broader industry trends. Registered direct offerings are a common method for companies to raise capital, often used to bypass more extensive public offering processes, but can lead to dilution for existing shareholders.

Comparison to Industry Standards

• The filing is a standard regulatory disclosure (Schedule 13D) required when a beneficial ownership threshold is met or significantly changed.
• The 79.1% ownership stake held by Citius Pharmaceuticals in Citius Oncology indicates a strong controlling interest, which is common in parent-subsidiary relationships, such as those seen with large pharmaceutical companies and their specialized oncology divisions (e.g., Pfizer's oncology unit or Novartis's Sandoz division).
• The specific financial terms or strategic implications of the registered direct offering are not detailed enough to compare against industry benchmarks for capital raises.

Stakeholder Impact

• Shareholders of Citius Pharmaceuticals, Inc.: Their indirect stake in Citius Oncology, Inc. has been diluted in terms of percentage ownership.
• Shareholders of Citius Oncology, Inc.: Existing shareholders (other than Citius Pharmaceuticals, Inc.) experienced dilution due to the issuance of new shares. New investors in the direct offering gained an equity stake.

Next Steps

• The filing does not explicitly mention future actions or milestones beyond the reporting of the ownership change.

Key Dates

Recommendation

The filing is a routine Schedule 13D amendment updating beneficial ownership after a registered direct offering by the subsidiary. It indicates a dilution of the parent company's percentage stake in the subsidiary. Without further information on the use of proceeds from the offering or the operational performance of Citius Oncology, Inc., a 'hold' recommendation is appropriate as this filing alone does not provide sufficient grounds for a significant change in investment thesis for Citius Pharmaceuticals, Inc.

Keywords

Citius Oncology, Citius Pharmaceuticals, Schedule 13D, Beneficial Ownership, Common Stock, Registered Direct Offering, Equity Stake, SEC Filing, Shareholding, Dilution